Erasca, Inc. (ERAS)
| Market Cap | 5.50B +631.0% |
| Revenue (ttm) | n/a |
| Net Income | -307.94M |
| EPS | -0.99 |
| Shares Out | 350.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,533,403 |
| Open | 15.29 |
| Previous Close | 15.78 |
| Day's Range | 14.12 - 15.84 |
| 52-Week Range | 2.46 - 24.28 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 24.11 (+53.96%) |
| Earnings Date | Nov 12, 2026 |
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ERAS stock is "Buy." The 12-month stock price target is $24.11, which is an increase of 53.96% from the latest price.
News
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 ...
Erasca Quarterly report: Q3 2026
Erasca has published its Q3 2026 quarterly earnings report on November 12, 2026.
Erasca Earnings release: Q3 2026
Erasca released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Erasca Transcript: Stifel 2026 Healthcare Conference 2026
ERAS-0015 is advancing toward a larger clinical update next week, with combination data guided for 1H 2027 and pivotal-trial starts targeted from 1H 2027. ERAS-4001’s 2H 2026 update will cover phase I safety, PK and initial activity.
Erasca Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Previously reported ERAS-0015 response rates were 40%-57% in pancreatic cancer and 60%+ in lung cancer, with expanded data expected at the November Triple Meeting. Planned pivotal studies span pancreatic and lung cancer, supported by a roughly $1 billion balance sheet.
Tango Therapeutics, Erasca initiate vopimetostat with ERAS-0015 study
Tango Therapeutics (TNGX) and Erasca (ERAS) announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted p...
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that ext...
Erasca to Present at Upcoming Conferences in November
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law.
Erasca participates in a conference call with JPMorgan
JPMorgan holds a conference call with management on October 5 at 1:30 pm. Webcast Link
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its ...
Erasca Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Promising clinical data for pan-RAS and pan-KRAS assets show high response rates and strong safety, supporting global registration trials and diverse combination strategies. Financial position is robust, enabling advancement through key milestones and collaborations.
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing...
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
Erasca price target raised to $33 from $25 at JPMorgan
JPMorgan raised the firm’s price target on Erasca (ERAS) to $33 from $25 and keeps an Overweight rating on the shares. The firm updated the company’s model following a competitive…
Erasca granted Fast Track Designation for ERAS-0015
Erasca (ERAS) announced that the FDA has granted Fast Track Designation to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. ERAS-0015 is an oral, highly potent pan-RA...
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung...
Erasca price target raised to $22 from $18 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Erasca (ERAS) to $22 from $18 and keeps a Buy rating on the shares. The firm cites the company’s clinical path for…
Erasca price target raised to $21 from $20 at Guggenheim
Guggenheim raised the firm’s price target on Erasca (ERAS) to $21 from $20 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q2 results.
Erasca price target raised to $20 from $18 at BofA
BofA raised the firm’s price target on Erasca (ERAS) to $20 from $18 and keeps a Neutral rating on the shares. The firm adjusted targets for several names in its…
Erasca reports Q2 EPS (14c), consensus (11c)
“Our mission is to deliver novel precision therapies that address unmet needs across a broad range of RAS-driven cancers, and we believe the encouraging early findings for ERAS-0015 represent an…
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combinati...
Erasca Earnings release: Q2 2026
Erasca released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Erasca Quarterly report: Q2 2026
Erasca has published its Q2 2026 quarterly earnings report on August 11, 2026.
Erasca Slides: Corporate presentation
Erasca has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.